| Topic | Articles |
| Gallbladder Cancer | Butte JM, et al. Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer. J Am Coll Surg. 2014 Sep;219(3):416-29. doi: 10.1016/j.jamcollsurg.2014.01.069. PMID: 25087941. D’Angelica M, et al. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009 Apr;16(4):806-16. doi: 10.1245/s10434-008-0189-3. PMID: 18985272. Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Jin LX, Weber SM, Salem A, Martin RC, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Merchant N, Cardona K, Maithel SK. A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. Ann Surg Oncol. 2017 May;24(5):1343-1350. doi: 10.1245/s10434-016-5637-x. PMID: 27812827. Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Jin LX, Weber SM, Salem A, Martin RC, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Kooby DA, Maithel SK. Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium. JAMA Surg. 2017 Feb 1;152(2):143-149. doi: 10.1001/jamasurg.2016.3642. PMID: 27784058. Ethun CG, Postlewait LM, Le N, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK. Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. J Surg Oncol. 2017 Jun;115(7):805-811. doi: 10.1002/jso.24591. PMID: 28230242. Gamboa AC, Maithel SK. The Landmark Series: Gallbladder Cancer. Ann Surg Oncol. 2020 Aug;27(8):2846-2858. Primrose JN, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25. Erratum in: Lancet Oncol. 2019 Apr 2;: PMID: 30922733. |
| Cholangiocarcinoma | Brindley PJ, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021 Sep 9;7(1):65. doi: 10.1038/s41572-021-00300-2. PMID: 34504109. Cloyd JM, Ejaz A, Pawlik TM. The Landmark Series: Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020 Aug;27(8):2859-2865. Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. 2013 Nov 15;119(22):3929-42. doi: 10.1002/cncr.28312. PMID: 23963845. Rea DJ, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61. doi: 10.1097/01.sla.0000179678.13285.fa. PMID: 16135931. Rocha FG, et al. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):490-6. doi: 10.1007/s00534-009-0205-4. PMID: 19806295. Soares KC, Jarnagin WR. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol. 2021 Aug;28(8):4158-4170. doi: 10.1245/s10434-021-09871-6. PMID: 33829358; PMCID: PMC9273057. Tao R, et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20;34(3):219-26. doi: 10.1200/JCO.2015.61.3778. Erratum in: J Clin Oncol. 2019 Apr 10;37(11):942. PMID: 26503201. |
| Benign Liver Tumors | |
| Hepatocellular Carcinoma | Cheng AL, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. PMID: 19095497. Finn RS, et al.; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PMID: 32402160. Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3. PMID: 33479224. Llovet JM, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. PMID: 18650514. Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693-9. doi: 10.1056/NEJM199603143341104. PMID: 8594428. |
| Liver Metastases | Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol. 2020 Sep;27(9):3270-3280. doi: 10.1245/s10434-020-08787-x. PMID: 32632880; PMCID: PMC7415723. Kawaguchi Y, Vauthey JN. The Landmark Series: RCTs Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis. Ann Surg Oncol. 2020 Oct;27(11):4263-4270. doi: 10.1245/s10434-020-08809-8. PMID: 32642998. |
| Pancreatic Adenocarcinoma | Dillhoff M, Pawlik TM. Role of Node Dissection in Pancreatic Tumor Resection. Ann Surg Oncol. 2021 Apr;28(4):2374-2381. See also: ASO Author Reflections: Role of Node Dissection in Pancreatic Tumor Resection. He J, et al. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Ann Surg Oncol. 2021 Mar;28(3):1514-1520. Rocha FG. Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Ann Surg Oncol. 2021 Mar;28(3):1400-1406. doi: 10.1245/s10434-020-09367-9. PMID: 33386541. Sachs TE, Tseng JF. Landmark Series in Pancreatic Tumors: Anastomotic Techniques and Route of Reconstruction. Ann Surg Oncol. 2021 Apr;28(4):2227-2234. Shah MM, Datta J, Merchant NB, Kooby DA. Landmark Series: Importance of Pancreatic Resection Margins. Ann Surg Oncol. 2022 Mar;29(3):1542-1550. doi: 10.1245/s10434-021-11168-7. PMID: 34985731. van Hilst J, et al. The Landmark Series: Minimally Invasive Pancreatic Resection. Ann Surg Oncol. 2021 Mar;28(3):1447-1456. doi: 10.1245/s10434-020-09335-3. PMID: 33341916; PMCID: PMC7892688. White RR, Murphy JD, Martin RCG. The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options. Ann Surg Oncol. 2021 Aug;28(8):4173-4180. |
| Non-PDAC Masses of the Pancreas | Tanaka M, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017 Sep-Oct;17(5):738-753. doi: 10.1016/j.pan.2017.07.007. PMID: 28735806. |
| Chronic Pancreatitis | |
| Bile Duct Injury | |
| Choledochal Cysts | |
| Gastric Cancer | Al-Batran SE, et al.; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. PMID: 30982686. Cunningham D, et al., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. doi: 10.1056/NEJMoa055531. PMID: 16822992. Dineen SP, Pimiento JM. The Landmark Series: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for Treatment of Gastric Cancer Metastatic to Peritoneum. Ann Surg Oncol. 2021 Aug;28(8):4130-4137. Ng SP, Leong T. Role of Radiation Therapy in Gastric Cancer. Ann Surg Oncol. 2021 Aug;28(8):4151-4157. |
| GIST | Keung EZ, et al. The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors. Ann Surg Oncol. 2020 Oct;27(10):3659-3671. |
HEPATOBILIARY SURGERY
Reply
Surgical Focus 